The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors - Trial NCT06381050
Access comprehensive clinical trial information for NCT06381050 through Pure Global AI's free database. This Phase 1 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Timeline & Enrollment
Phase 1
May 01, 2024
Apr 01, 2027
Primary Outcome
Maximum tolerated dose (MTD) or maximum administered dose (MAD),Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) (CTCAE v5.0)
Summary
This study is an open-label, phase I clinical trial of SHR-7631 in patients with advanced
 solid tumors. The whole study is divided into three stages: dose escalation, dose expansion
 and efficacy expansion.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06381050
Non-Device Trial